News
Article
FDA Approves Impax’s Generic Version of Intuniv (Guanfacine) Extended-Release Tablets
Author(s):
Impax Laboratories announced that FDA has approved its generic version of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg, and 4 mg.
Impax Laboratories announced that FDA has approved its generic version of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg, and 4 mg. The drug is used for the treatment of attention deficit hyperactivity disorder in children and adolescents ages six to 17.
Figures from IMS Health showed that US brand and generic sales of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg, and 4 mg were approximately $689 million for the 12 months ending in August 2015.
Source: Impax
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
